News
Dr. Reddy’s Rituximab Biosimilar Wins US FDA Approval
Fresenius Kabi holds the exclusive rights to commercialize Dr. Reddy’s Rituximab Biosimilar in the United States.
E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Fresenius Kabi holds the exclusive rights to commercialize Dr. Reddy’s Rituximab Biosimilar in the United States.
HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
